AngioDynamics, Inc. (ANGO) Trading Down 6.4%
AngioDynamics, Inc. (NASDAQ:ANGO)’s share price dropped 6.4% during trading on Tuesday . The stock traded as low as $15.21 and last traded at $15.46, with a volume of 3,077,677 shares trading hands. The stock had previously closed at $16.52.
ANGO has been the subject of several research reports. KeyCorp lowered their price objective on shares of AngioDynamics from $17.00 to $16.00 and set an “overweight” rating for the company in a research report on Friday, April 8th. Zacks Investment Research raised shares of AngioDynamics from a “sell” rating to a “hold” rating in a research note on Wednesday, June 8th. Canaccord Genuity downgraded shares of AngioDynamics from a “buy” rating to a “hold” rating and reduced their target price for the company from $14.50 to $13.00 in a research note on Tuesday, April 5th. Finally, Piper Jaffray Cos. started coverage on shares of AngioDynamics in a research note on Friday, April 8th. They issued a “neutral” rating and a $12.00 target price on the stock. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $14.10.
The company’s market cap is $554.50 million. The company has a 50-day moving average of $14.92 and a 200-day moving average of $12.43.
AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Wednesday, July 13th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.16 by $0.03. During the same period in the previous year, the firm posted $0.14 EPS. The company earned $93.40 million during the quarter, compared to analysts’ expectations of $88.64 million. AngioDynamics’s revenue was up 2.8% compared to the same quarter last year. On average, analysts forecast that AngioDynamics, Inc. will post $0.63 earnings per share for the current fiscal year.
In related news, VP Charles R. Greiner sold 3,508 shares of the business’s stock in a transaction on Friday, May 6th. The shares were sold at an average price of $12.31, for a total value of $43,183.48. Following the completion of the sale, the vice president now owns 20,910 shares of the company’s stock, valued at approximately $257,402.10. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
A number of large investors have made changes to their positions in the company. Nationwide Fund Advisors boosted its stake in shares of AngioDynamics by 252.9% in the fourth quarter. Nationwide Fund Advisors now owns 88,374 shares of the company’s stock valued at $1,073,000 after buying an additional 63,332 shares during the period. Morgan Stanley boosted its stake in shares of AngioDynamics by 6.2% in the fourth quarter. Morgan Stanley now owns 98,634 shares of the company’s stock valued at $1,198,000 after buying an additional 5,728 shares during the period. Whitebox Advisors LLC acquired a new stake in shares of AngioDynamics during the fourth quarter valued at about $1,384,000. Royce & Associates LLC boosted its stake in shares of AngioDynamics by 19.0% in the fourth quarter. Royce & Associates LLC now owns 640,801 shares of the company’s stock valued at $7,779,000 after buying an additional 102,098 shares during the period. Finally, Lapides Asset Management LLC boosted its stake in shares of AngioDynamics by 1.2% in the fourth quarter. Lapides Asset Management LLC now owns 700,500 shares of the company’s stock valued at $8,504,000 after buying an additional 8,400 shares during the period.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.